Emerging roles of endothelial cells and smooth muscle cells in transplant vascular disease

Transplantation Reviews

Volumn 13, Issue 3, 1999, Pages 109-127

  McDonald, Paul C ^a   Wong, Donald ^b   Granville, David J ^a   McManus, Bruce M ^c  

^a HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^b Pharmaceutical Manufacturing Association of Canada   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Endothelial cells; Smooth muscle cells; Transplant vascular disease

Indexed keywords

EID: 0001285475     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-470X(99)80070-6     Document Type: Article

References (206)

1. Ventura HO, Mehra MR, Smart FW, et al: Cardiac allograft vasculopathy: Current concepts. Am Heart J 1995, 129:791
2. Dong C, Redenbach D, Wood S, et al: The pathogenesis of cardiac allograft vasculopathy. Curr Opin Cardiol 1996, 11:183
3. Weis M, von Scheidt W: Cardiac allograft vasculopathy. A review. Circulation 1997, 96:2069
4. Andersen HO, Holm P, Stender S, et al: Relative importance of ischemic injury and immunological injury on the development of transplant arteriosclerosis in rabbit aortic allografts. Transplantation 1995, 60:631
5. Young-Ramsaran JO, Hruban RH, Hutchins GM, et al: Ultrastructural evidence of cell-mediated endothelial cell injury in cardiac transplant-related accelerated arteriosclerosis. Ultrastruct Pathol 1993, 17:125
6. Hansson GK: Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997, 8:301
7. Lin H, Wilson JE, Kendall TJ, et al: Comparable proximal and distal severity of intimal thickening and size of epicardial coronary arteries in transplant arteriopathy of human cardiac allografts. J Heart Lung Transplant 1994, 13:824
8. McManus BM, Malcolm G, Kendall TJ, et al: Lipid overload and proteoglycan expression in chronic rejection of the human transplanted heart. Clin Transplant 1994, 8:336
9. Lin H, Ignatescu M, Wilson JE, et al: Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: Geographic relationship to vessel wall proteoglycans. J Heart Lung Transplant 1996, 15: 1223
10. McManus BM, Horley KJ, Wilson JE, et al: Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy. Am J Pathol 1995, 147:293
11. McDonald PC, Kenyon JA, McManus BM: The role of lipids in transplant vascular disease. Lab Invest 1998, 78:1187
12. Lin H, Wilson JE, Roberts CR, et al: Biglycan, decorin, and versican protein expression patterns in coronary arteriopathy of human cardiac allograft: Distinctness as compared to native atherosclerosis. J Heart Lung Transplant 1996, 15: 1233
13. Dong C, Wilson JE, Winters GL, et al: Human transplant coronary artery disease: Pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest 1996, 74:921
14. Dong C, Wilson J, Winters G, et al: Fas-mediated cytotoxicity: A potential role in transplant coronary artery disease of human cardiac allografts. J Heart Lung Transplant 1996, 15:S97
15. Carvalho D, Savage C: Cytokines, adhesion molecules, anti-endothelial cell autoantibodies and vascular disease. Cardiovasc Pathol 1997, 6:61
16. Rose ML: Role of endothelial cells in allograft rejection. Vasc Med 1997, 2:105
17. Fuggle SV, Koo DD: Cell adhesion molecules in clinical renal transplantation. Transplantation 1998, 65:763
18. Hinek A: Adhesion molecules and cell surface receptors in the heart transplant-associated arteriosclerosis. Folia Histochem Cytobiol 1996, 34:3
19. Libby P: Do vascular wall cytokines promote atherogenesis? Hosp Pract 1992, 27:51
20. Mantovani A, Sozzani S, Vecchi A, et al: Cytokine activation of endothelial cells: New molecules for an old paradigm. Thromb Haemost 1997, 78:406
21. Ginsberg M, Ruggeri Z, Varki AP: Cell adhesion in vascular biology supplement. J Clin Invest 1997, 100 (suppl 11)
22. Cines DB, Pollak ES, Buck CA, et al: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527
23. McGill SN, Ahmed NA, Christou NV: Endothelial cells: Role in infection and inflammation. World J Surg 1998, 22:171
24. Russell PS, Chase CM, Winn HJ, et al: Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-gamma. Transplantation 1994, 57:1367
25. Russell PS, Chase CM, Colvin RB: Coronary atherosclerosis in transplanted mouse hearts. IV Effects of treatment with monoclonal antibodies to intercellular adhesion molecule-1 and leukocyte function-associated antigen-1. Transplantation 1995, 60:724
26. Akyurek ML, Funa K, Wanders A, et al: Expression of CD11b and ICAM-1 in an in vivo model of transplant arteriosclerosis. Transpl Immunol 1995, 3:107
27. Labarrere CA, Nelson DR, Faulk WP: Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA 1997, 278:1169
28. Geerling RA, Ansari AA, LaFond-Walker AM, et al: Accelerated arteriosclerosis in aortic grafts: A role for cytokines in progressive intimai lesion development. Transplant Proc 1998, 30:946
29. Tedgui A, Bernard C: Cytokines, immuno-inflammatory response and atherosclerosis. Eur Cytokine Netw 1994, 5:263
30. Suzuki J, Isobe M, Yamazaki S, et al: Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. J Heart Lung Transplant 1997, 16:1141
31. Molossi S, Elices M, Arrhenius T, et al: Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J Clin Invest 1995, 95:2601
32. Korom S, Hancock WW, Coito AJ, et al: Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients. II. Treatment with connecting segment-1 peptides prevents chronic rejection by attenuating arteriosclerotic development and suppressing intragraft T cell and macrophage activation. Transplantation 1998, 65:854
33. Nagano H, Libby P, Taylor MK, et al: Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: Role of interferon-gamma. Am J Pathol 1998, 152:1187
34. Raisanen-Sokolowski A, Glysing-Jensen T, Koglin J, et al: Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients. Am J Pathol 1998, 152:359
35. Nagano H, Mitchell RN, Taylor MK, et al: Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997, 100:550
36. Koskinen PK, Lemstrom KB: Adhesion molecule P-selectin and vascular cell adhesion molecule-1 in enhanced heart allograft arteriosclerosis in the rat. Circulation 1997, 95:191
37. Clausell N, Molossi S, Sett S, et al: In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation 1994, 89:2768
38. Molossi S, Clausell N, Rabinovitch M: Coronary artery endothelial interleukin-1 beta mediates enhanced fibronectin production related to post-cardiac transplant arteriopathy in piglets. Circulation 1993, 88:II248
39. Karnovsky MJ, Russell ME, Hancock W, et al: Chronic rejection in experimental cardiac transplantation in a rat model. Clin Transplant 1994, 8:308
40. Boisvert WA, Santiago R, Curtiss LK, et al: A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998, 101:353
41. Pattison JM, Nelson PJ, Huie P, et al: RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 1996, 15:1194
42. Shaddy RE, Hansen JC, Cowley CG: Effects of T cells on platelet-derived growth factor-like protein secretion from endothelial cells. J Heart Lung Transplant 1992, 11:48
43. Rubin K, Tingstrom A, Hansson GK, et al: Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: Possible implications for development of vascular proliferative lesions. Lancet 1988, 1:1353
44. Hosenpud JD, Morris TE, Shipley GD, et al: Cardiac allograft vasculopathy. Preferential regulation of endothelial cell-derived mesenchymal growth factors in response to a donor-specific cell-mediated allogeneic response. Transplantation 1996, 61:939
45. Motomura N, Lou H, Maurice P, et al: Acceleration of arteriosclerosis of the rat aorta allograft by insulin growth factor-I. Transplantation 1997, 63:932
46. Motomura N, Lou H, Orskov H, et al: Exposure of vascular allografts to insulin-like growth factor-I (IGF-I) increases vascular expression of IGF-I ligand and receptor protein and accelerates arteriosclerosis in rats. Transplantation 1998, 65:1024
47. Hayry P, Aavik E, Myllarniemi M: Blockade of growth factor synthesis and growth factor action: TWO possible sites of interference in allograft vessel disease and coronary bypass or balloon injury. Metabol Clin Exp 1996, 45:101 (suppl 1)
48. Waltenberger J, Akyurek ML, Aurivillius M, et al: Ischemia-induced transplant arteriosclerosis in the rat. Induction of peptide growth factor expression. Arterioscler Thromb Vasc Biol 1996, 16:1516
49. Poston RS Jr, Billingham ME, Pollard J, et al: Effects of increased ICAM-I on reperfusion injury and chronic graft vascular disease. Ann Thorac Surg 1997, 64:1004
50. Granville DJ, Carthy CM, Hunt DW, et al: Apoptosis: Molecular aspects of cell death and disease. Lab Invest 1998, 78:893
51. Pang XP, Hershman JM, Karsan A: TNF-alpha induction of A1 expression in human cancer cells. Oncol Res 1997, 9:623
52. Stehlik C, de Martin R, Kumabashiri I, et al: Nuclear factor (NF)-kappa B-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor-alpha-induced apoptosis. J Exp Med 1998, 188:211
53. Sata M, Walsh K: TNF-alpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nature Med 1998, 4:415
54. Sata M, Walsh K: Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J Clin Invest 1998, 102:1682
55. Armstrong AT, Strauch AR, Kardan A, et al: Morphometric and immunocytochemical analysis of coronary arterioles in human transplanted hearts. J Heart Lung Transplant 1996, 15:818
56. Billingham ME: Histopathology of graft coronary disease. J Heart Lung Transplant 1992, 11:S38
57. Adams DH, Karnovsky MJ: Hypercholesterolemia does not exacerbate arterial intimai thickening in chronically rejecting rat cardiac allografts. Transplant Proc 1989, 21:437
58. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993, 362:801
59. Schwartz SM, deBlois D, O'Brien ERM: The intima. Soil for atherosclerosis and restenosis. Circ Res 1995, 77:445
60. Sanders M: Molecular and cellular concepts in atherosclerosis. Pharmacol Ther 1994, 61:109
61. Basha BJ, Sowers JR: Atherosclerosis: An update. Am Heart J 1996, 131:1192
62. Clausell N, Rabinovitch M: Upregulation of fibronectin synthesis by interleukin-1 beta in coronary artery smooth muscle cells is associated with the development of the post-cardiac transplant arteriopathy in piglets. J Clin Invest 1993, 92:1850
63. Molossi S, Clausell N, Rabinovitch M: Reciprocal induction of tumor necrosis factor-alpha and interleukin-1 beta activity mediates fibronectin synthesis in coronary artery smooth muscle cells. J Cell Physiol 1995, 163:19
64. Cowan B, Baron O, Crack J, et al: Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits after heterotopic cardiac transplantation. J Clin Invest 1996, 97: 2452
65. Akyurek LM, Paul LC, Funa K, et al: Smooth muscle cell migration into intima and adventitia during development of transplant vasculopathy. Transplantation 1996, 62:1526
66. Lemstrom KB, Koskinen PK: Expression and localization of platelet-derived growth factor ligand and receptor protein during acute and chronic rejection of rat cardiac allografts. Circulation 1997, 96:1240
67. Alpers CE, Davis CL, Barr D, et al: Identification of platelet-derived growth factor A and B chains in human renal vascular rejection. Am J Pathol 1996, 148:439
68. Floege J, Hudkins KL, Davis CL, et al: Expression of PDGF alpha-receptor in renal arteriosclerosis and rejecting renal transplants. J Am Soc Nephrol 1998, 9:211
69. Lou H, Kodama T, Wang YN, et al: L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6. J Heart Lung Transplant 1996, 15:1248
70. Mennander A, Paavonen T, Hayry P: Intimal thickening and medial necrosis in allograft arteriosclerosis (chronic rejection) are independently regulated. Arterioscler Thromb Vasc Biol 1993, 13:1019
71. Bjorkerud S, Bjorkerud B: Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996, 149:367
72. Lee RT, Libby P: The unstable atheroma. Arterioscler Thromb Vasc Biol 1997, 17:1859
73. Isner JM, Kearney M, Bortman S, et al: Apoptosis in human atherosclerosis and restenosis. Circulation 1995, 91:2703
74. Han DK, Haudenschild CC, Hong MK, et al: Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol 1995, 147:267
75. Perlman H, Maillard L, Krasinski K, et al: Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation 1997, 95:981
76. Haunstetter A, Izumo S: Apoptosis: Basic mechanisms and implications for cardiovascular disease. Circ Res 1998, 82: 1111
77. Bochaton-Piallat ML, Gabbiani F, Redard M, et al: Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol 1995, 146:1059
78. Fukuo K, Hata S, Suhara T, et al: Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 1996, 27:823
79. Bennett MR, Littlewood TD, Schwartz SM, et al: Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis. Circ Res 1997, 81:591
80. Bennett MR, Evan GI, Schwartz SM: Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995, 95:2266
81. Geng YJ, Henderson LE, Levesque EB, et al: Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:2200
82. Nose M, Ito MR, Ono M, et al: Vascular lesions in mice with a deficit in Fas-mediated apoptosis and their transfer. Int J Cardiol 1996, 54(suppl):S11
83. Geng YJ, Wu Q, Muszynski M, et al: Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 1996, 16:19
84. Libby P, Hansson GK: Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991, 64:5
85. Wight TN: The vascular extracellular matrix, in Fuster V, Ross R, Topol FJ (eds): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippincott-Raven, 1996, p421
86. Evanko SP, Raines EW, Ross R, et al: Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-β. Am J Pathol 1998, 152:533
87. Wight TN, Lara S, Riessen R, et al: Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries. Am J Pathol 1997, 151:963
88. Lin H, Kanda T, Hoshino Y, et al: Versican, biglyran, and decorin protein expression patterns in coronary arteries - Analysis of primary and restenotic lesions. Cardiovasc Pathol 1998, 7:31
89. Schonherr E, Jarvelainen HT, Sandell LJ, et al: Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem 1991, 266:17640
90. Schonherr E, Jarvelainen HT, Kinsella MG, et al: Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglyran and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb Vasc Biol 1993, 13:1026
91. Edwards IJ, Xu H, Wright MJ, et al: Interleukin-1 upregulates decorin production by arterial smooth muscle cells. Arterioscler Thromb Vasc Biol 1994, 14:1032
92. Schonherr E, Kinsella MG, Wight TN: Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch Biochem Biophys 1997, 339:353
93. Liu J, Fitzli D, Liu M, et al: PDGF-induced grycosaminoglycan synthesis is mediated via phosphatidylinositol 3-kinase. Am J Physiol 1998, 274:L702
94. Deudon E, Berrou E, Breton M, et al: Growth-related production of proteoglycans and hyaluronic acid in synchronous arterial smooth muscle cells. Int J Biochem 1992, 24:465
95. Breton M, Berrou E, Brahimi-Horn MC, et al: Synthesis of sulfated proteoglycans throughout the cell cycle in smooth muscle cells from pig aorta. Exp Cell Res 1986, 166:416
96. Tao Z, Smart FW, Figueroa JE, et al: Elevated expression of proteoglycans in proliferating vascular smooth muscle cells. Atherosclerosis 1997, 135:171
97. Dreher KL, Asundi V, Matzura D, et al: Vascular smooth muscle biglycan represents a highly conserved proteoglycan within the arterial wall. Eur J Cell Biol 1990, 53:296
98. Emoto N, Onose H, Yamada H, et al: Growth factors increase pericellular proteoglycans independently of their mitogenic effects on A10 rat vascular smooth muscle cells. Int J Biochem Cell Biol 1998, 30:47
99. Rasmussen LM, Wolf YG, Ruoslahti E: Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-beta activity. Am J Pathol 1995, 147:1041
100. Hidalgo MA, Sarathchandra P, Fryer PR, et al: Scanning electron microscopic changes in morphology of pulmonary endothelium in rat lung isografts following hypothermic ischaemic storage and transplantation. Int J Exp Pathol 1995, 76:339
101. Hidalgo MA, Shah KA, Fuller BJ, et al: Cold ischemia-induced damage to vascular endothelium results in permeability alterations in transplanted lungs. J Thorac Cardiovasc Surg 1996, 112:1027
102. Mii S, Okadome K, Onohara T, et al: Intimal thickening and permeability of arterial autogenous vein graft in a canine poor-runoff model: Transmission electron microscopic evidence. Surgery 1990, 108:81
103. Eguchi H, Okadome K, Mii S, et al: Significance of the endothelial lining in prevention of intimal thickening of autogenous vein grafts in dogs. J Surg Res 1991, 50:179
104. Forbes RD, Guttmann RD, Gomersall M, et al: A controlled serial ultrastructural tracer study of first-set cardiac allograft rejection in the rat. Evidence that the microvascular endothelium is the primary target of graft destruction. Am J Pathol 1983, 111:184
105. Wojciak-Stothard B, Entwistle A, Garg R, et al: Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol 1998, 176:150
106. Ramos MA, Kuzuya M, Esaki T, et al: Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1998, 18:1188
107. Couffinhal T, Kearney M, Witzenbichler B, et al: Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997, 150:1673
108. Torry RJ, Labarrere CA, Torry DS, et al: Vascular endothelial growth factor expression in transplanted human hearts. Transplantation 1995, 60:1451
109. Abedi H, Zachary I: Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997, 272:15442
110. Schmid E, Muller TH, Budzinski RM, et al: Lymphocyte adhesion to human endothelial cells induces tissue factor expression via a juxtacrine pathway. Thromb Haemost 1995, 73:421
111. Damle NK, Doyle LV: Ability of human T lymphocytes to adhere to vascular endothelial cells and to augment endothelial permeability to macromolecules is linked to their state of post-thymic maturation. J Immunol 1990, 144:1233
112. Damle NK, Doyle LV: IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. J Immunol 1989, 142: 2660
113. 2+ mobilization. Eur J Immunol 1997, 27:1530
114. Gurubhagavatula I, Amrani Y, Pratico D, et al: Engagement of human PECAM-I (CD31) on human endothelial cells increases intracellular calcium ion concentration and stimulates prostacyclin release. J Clin Invest 1998, 101:212
115. Pfau S, Leitenberg D, Rinder H, et al: Lymphocyte adhesion-dependent calcium signaling in human endothelial cells. J Cell Biol 1995, 128:969
116. Lorenzon P, Vecile E, Nardon E, et al: Endothelial cell E- and P-selectin and vascular cell adhesion molecule-1 function as signaling receptors. J Cell Biol 1998, 142:1381
117. Huang AJ, Manning JE, Bandak TM, et al: Endothelial cell cytosolic free calcium regulates neutrophil migration across monolayers of endothelial cells. J Cell Biol 1993, 120:1371
118. Baldwin WM III, Pruitt SK, Brauer RB, et al: Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation 1995, 59:797
119. Zales VR, Crawford S, Backer CL, et al: Spectrum of humoral rejection after pediatric heart transplantation. J Heart Lung Transplant 1993, 12:563
120. Brauer RB, Baldwin WM III, Ibrahim S, et al: The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat. Transplantation 1995, 59:288
121. Kolb F, Heudes D, Mandet C, et al: Presensitization accelerates allograft arteriosclerosis. Transplantation 1996, 62:1401
122. Saadi S, Platt JL: Transient-perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 1995, 181:21
123. Suttorp N, Bhakdi S: Terminal complement complex and endothelial cells. Z Kardiol 1989, 78(suppl 6): 140
124. Pruitt SK, Bollinger RR, Collins BH, et al: Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. Transplantation 1997, 63:900
125. Jakobs FM, Davis EA, White T, et al: Prolonged discordant xenograft survival by inhibition of the intrinsic coagulation pathway in complement C6-deficient recipients. J Heart Lung Transplant 1998, 17:306
126. Davis EA, Lam TT, Qian Z, et al: Inhibition of neutrophil adhesion and the membrane attack complex of complement synergistically prolongs cardiac xenograft survival. J Heart Lung Transplant 1995, 14:973
127. Qian Z, Jakobs FM, Pfaff-Amesse T, et al: Complement contributes to the rejection of complete and class I major histocompatibility complex - incompatible cardiac allografts. J Heart Lung Transplant 1998, 17:470
128. Tanaka Y, Albelda SM, Horgan KJ, et al: CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. J Exp Med 1992, 176:245
129. Berman ME, Muller WA: Ligation of platelet/endothelial cell adhesion molecule 1 (PECAM-1/CD31) on monocytes and neutrophils increases binding capacity of leukocyte CR3 (CD11b/CD18). J Immunol 1995, 154:299
130. Piali L, Albelda SM, Baldwin HS, et al: Murine platelet endothelial cell adhesion molecule (PECAM-1)/CD31 modulates beta 2 integrins on lymphokine-activated killer cells. Eur J Immunol 1993, 23:2464
131. Nielsen LB. Transfer of low-density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 1996, 123:1
132. van Hinsbergh VW, Havekes L, Emeis JJ, et al: Low-density lipoprotein metabolism by endothelial cells from human umbilical cord arteries and veins. Arteriosclerosis 1983, 3:547
133. Vasile E, Simionescu M, Simionescu N: Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ. J Cell Biol 1983, 96:1677
134. Robinson CS, Wagner RC: Differential endocytosis of lipoproteins by capillary endothelial vesicles. Microcirc Endothel Lymph 1985, 2:313
135. Descamps L, Cecchelli R, Torpier G: Effects of tumor necrosis factor on receptor-mediated endocytosis and barrier functions of bovine brain capillary endothelial cell monolayers. J Neuroimmunol 1997, 74:173
136. Higazi AA, Lavi E, Bdeir K, et al: Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 1997, 89:4290
137. Sprague EA, Steinbach BL, Nerem RM, et al: Influence of a laminar steady-state fluid-imposed wall shear stress on the binding, internalization, and degradation of low-density lipoproteins by cultured arterial endothelium. Circulation 1987, 76:648
138. Holland JA, Pritchard KA, Rogers NJ, et al: Atherogenic levels of low-density lipoprotein increase endocytotic activity in cultured human endothelial cells. Am J Pathol 1992; 140:551
139. Holland JA, Ziegler LM, Meyer JW: Atherogenic levels of low-density lipoprotein increase hydrogen peroxide generation in cultured human endothelial cells: Possible mechanism of heightened endocytosis. J Cell Physiol 1996, 166:144
140. Winters GL, Kendall TJ, Radio SJ, et al: Posttransplant obesity and hyperlipidemia: Major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transplant 1990, 9:364
141. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551
142. O'Brien K, Olin KL, Alpers CE, et al: Comparison of apolipoprotein and proteoglycan deposits in human coronaryatherosclerotic plaques: Colocalization of biglycan with apolipoproteins. Circulation 1998, 98:519
143. Olsson U, Camejo G, Hurt-Camejo E, et al: Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. Arterioscler Thromb Vasc Biol 1997, 17:149
144. Hurt-Camejo E, Olsson U, Wiklund O, et al: Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 1997, 17:1011
145. Vijayagopal P, Figueroa JE, Fontenot JD, et al: Isolation and characterization of a proteoglycan variant from human aorta exhibiting a marked affinity for low-density lipoprotein and demonstration of its enhanced expression in atherosclerotic plaques. Atherosclerosis 1996, 127:195
146. Camejo G, Fager G, Rosengren B, et al: Binding of low-density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem 1993, 268:14131
147. Kruse R, Merten M, Yoshida K, et al: Cholesterol-dependent changes of glyrosaminoglycan pattern in human aorta. Basic Res Cardiol 1996, 91:344
148. Hurt-Camejo E, Camejo G, Rosengren B, et al: Effect of arterial proteoglycans and glycosaminoglycans on low-density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb Vasc Biol 1992, 12:569
149. Vijayagopal P, Glancy DL: Macrophages stimulate cholesteryl ester accumulation in cocultured smooth muscle cells incubated with lipoprotein-proteoglycan complex. Arterioscl Thromb Vasc Biol 1996, 16:1112
150. Vijayagopal P: Enhanced synthesis and accumulation of proteoglycans in cholesterol-enriched arterial smooth muscle cells. Biochem J 1993, 294:603
151. Vijayagopal P, Figueroa JE, Guo Q, et al: Marked alteration of proteoglycan metabolism in cholesterol-enriched human arterial smooth muscle cells. Biochem J 1996, 315:995
152. Camejo G, Hurt-Camejo E, Rosengren B, et al: Modification of copper-catalyzed oxidation of low-density lipoprotein by proteoglycans and glycosaminoglycans. J Lipid Res 1991, 32:1983
153. Oorni K, Pentikainen MO, Annila A, et al: Oxidation of low-density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues. J Biol Chem 1997, 272:21303
154. Steinbrecher UP, Zhang HF, Lougheed M: Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med 1990, 9:155
155. Steinberg D: Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997, 95:1062
156. Steinberg D: Low-density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997, 272:20963
157. Navab M, Berliner JA, Watson AD, et al: The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996, 16:831
158. Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915
159. Hajjar DP, Haberland ME: Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem 1997, 272:22975
160. Kuzuya M, Satake S, Esaki T, et al: Induction of angiogenesis by smooth muscle cell-derived factor: Possible role in neovascularization in atherosclerotic plaque. J Cell Physiol 1995, 164:658
161. Allen S, Khan S, Al-Mohanna F, et al: Native low-density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J Clin Invest 1998, 101:1064
162. Chatterjee S, Ghosh N: Oxidized low-density lipoprotein stimulates aortic smooth muscle cell proliferation. Glycobiology 1996, 6:303
163. Chatterjee S: Role of oxidized human plasma low-density lipoproteins in atherosclerosis: Effects on smooth muscle cell proliferation. Mol Cell Biochem 1992, 111:143
164. Gorog P: Modified low-density lipoprotein is a potent stimulus for smooth muscle cell outgrowth from rat aortic expiant in vitro. Atherosclerosis 1997, 129:1
165. Auge N, Escargueil-Blanc I, Lajoie-Mazenc I, et al: Potential role for ceramide in mitogen-activated protein kinase activation and proliferation of vascular smooth muscle cells induced by oxidized low-density lipoprotein. J Biol Chem 1998, 273:12893
166. Oinuma T, Yamada T, Sakurai I: Effects of copper-zinc type superoxide dismutase on the proliferation and migration of cultured vascular smooth muscle cells induced by oxidized low density lipoprotein. J Atheroscler Thromb 1997, 4:79
167. Gorog P, Kovacs IB: Inhibition of vascular smooth muscle cell migration by intact endothelium is nitric oxide-mediated: Interference by oxidised low-density lipoproteins. J Vasc Res 1998, 35:165
168. Dulak J, Polus M, Guevara I, et al: Regulation of inducible nitric oxide synthase (iNOS) and GTP cyclohydrolase I (GTP-CH 1) gene expression by ox-LDL in rat vascular smooth muscle cells. J Physiol Pharmacol 1997, 48:689
169. Ishigami M, Swertfeger DK, Granholm NA, et al: Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem 1998, 273:20156
170. Shi CW, Lee WS, Russell ME, et al: Hypercholesterolemia exacerbates transplant arteriosclerosis via increased neointimal smooth muscle cell accumulation - Studies in apolipoprotein E knockout mice. Circulation 1997, 96:2722
171. Dimmeler S, Zeiher AM: Nitric oxide and apoptosis: Another paradigm for the double-edged role of nitric oxide. Nitric Oxide 1997, 1:275
172. Walter DH, Haendeler J, Galle J, et al: Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. Circulation 1998, 98:1153
173. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309
174. Andersen HO, Madsen G, Nordestgaard BG, et al: Cyclosporin suppresses transplant arteriosclerosis in the aorta-allografted, cholesterol-clamped rabbit. Suppression preceded by decrease in arterial lipoprotein permeability. Arterioscler Thromb Vasc Biol 1994, 14:944
175. Drew AF, Tipping PG: Cyclosporine treatment reduces early atherosclerosis in the cholesterol- fed rabbit. Atherosclerosis 1995, 116:181
176. Handa N, Hatanaka M, Baumgartner WA, et al: Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts. Transplantation 1993, 56:535
177. Vriens PW, Blankenberg FG, Stoot JH, et al: The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg 1998, 116:844
178. Bellon JM, Bujan MJ, Jurado F, et al: Atherogenic effects of cyclosporine in an experimental model of arterial autograft. Transplantation 1995, 60:407
179. Roselaar SE, Schonfeld G, Daugherty A: Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest 1995, 96:1389
180. Escargueil-Blanc I, Meilhac O, Pieraggi MT, et al: Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway. Prevention by aunntricarboxylic acid. Arterioscler Thromb Vasc Biol 1997, 17:331
181. Dimmeler S, Haendeler J, Nehls M, et al: Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 beta-converting enzyme (ICE)-Iike and cysteine protease protein (CPP)-32-like proteases. J Exp Med 1997, 185:601
182. Ren Y, Savill J: Apoptosis: The importance of being eaten. Cell Death Differ 1998, 5:563
183. Fadok VA, Bratton DL, Frasch SC, et al: The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ 1998, 5:551
184. Sambrano GR, Steinberg D: Recognition of oxidatively damaged and apoptotic cells by an oxidized low-density lipoprotein receptor on mouse peritoneal macrophages: Role of membrane phosphatidylserine. Proc Natl Acad Sci U S A 1995, 92:1396
185. Oka K, Sawamura T, Kikuta K, et al: Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci USA 1998, 95:9535
186. Bombeli T, Karsan A, Tait JF, et al: Apoptotic vascular endothelial cells become procoagulant. Blood 1997, 89:2429
187. Bevers EM, Comfurius P, Dekkers DW, et al: Transmembrane phospholipid distribution in blood cells: Control mechanisms and pathophysiological significance. Biol Chem 1998, 379:973
188. Flynn PD, Byrne CD, Baglin TP, et al: Thrombin generation by apoptotic vascular smooth muscle cells. Blood 1997, 89:4378
189. Kinscherf R, Deigner HP, Usinger C, et al: Induction of mitochondrial manganese superoxide dismutase in macrophages by oxidized LDL: Its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits. FASEB J 1997, 11:1317
190. Yun JK, McCormick TS, Villabona C, et al: Inflammatory mediators are perpetuated in macrophages resistant to apoptosis induced by hypoxia. Proc Natl Acad Sci USA 1997, 94:13903
191. Yuan XM, Li W, Olsson AG, et al: The toxicity to macrophages of oxidized low-density lipoprotein is mediated through lysosomal damage. Atherosclerosis 1997, 133:153
192. Russell ME: Macrophages and transplant arteriosclerosis: Known and novel molecules. J Heart Lung Transplant 1995;14:S111
193. Russell ME: Graft arteriosclerosis: Molecular features of macrophage activation. Transplant Proc 1997, 29:2542
194. Liu ZQ, Wildhirt SM, Weismuller S, et al: Nitric oxide and endothelin in the development of cardiac allograft vasculopathy - Potential targets for therapeutic interventions. Atherosclerosis 1998, 140:1
195. Koglin J, Glysing-Jensen T, Mudgett JS, et al: Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation 1998, 97:2059
196. Ravalli S, Albala A, Ming M, et al: Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease. Circulation 1998, 97:2338
197. Akyurek LM, Fellstrom BC, Yan ZQ, et al: Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. Am J Pathol 1996, 149:1981
198. Russell ME, Wallace AF, Wyner LR, et al: Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995, 92:457
199. Lafond-Walker A, Chen CL, Augustine S, et al: Inducible nitric oxide synthase expression in coronary arteries of transplanted human hearts with accelerated graft arteriosclerosis. Am J Pathol 1997, 151:919
200. Dusting GJ, Macdonald PS: Endogenous nitric oxide in cardiovascular disease and transplantation. Ann Med 1995, 27:395
201. Shears LL, Kawaharada N, Tzeng E, et al: Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 1997, 100:2035
202. Little TL, Beyer EC, Duling BR: Connexin 43 and connexin 40 gap junctional proteins are present in arteriolar smooth muscle and endothelium in vivo. Am J Physiol 1995, 268: H729
203. Hu J, Cotgreave IA: Differential regulation of gap junctions by proinflammatory mediators in vitro. J Clin Invest 1997, 99:2312
204. Haas TL, Duling BR: Morphology favors an endothelial cell pathway for longitudinal conduction within arterioles. Microvase Res 1997, 53:113
205. Little TL, Xia J, Duling BR: Dye tracers define differential endothelial and smooth muscle coupling patterns within the arteriolar wall. Circ Res 1995, 76:498
206. Chaytor AT, Evans WH, Griffith TM: Central role of heterocellular gap junctional communication in endothelium-dependent relaxations of rabbit arteries. J Physiol 1998, 508:561